


ICON to present successful late phase, outcomes research at ISPOR 2012

24 April 2012 | News | By BioSpectrum Bureau

ICON to present successful late phase, outcomes research at ISPOR 2012



Singapore: ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced details of its participation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual Meeting, taking place from June 2-6 in Washington, DC.

ICON, Oxford Outcomes and PriceSpective experts will speak at 22 educational and poster sessions on a range of topics, including observational research, advanced decision modelling on health economic evaluations, approaches for value based pricing, biosimilars and early stage economic models to integrate clinical and commercial development. Also at the event, Dr Mark Sculpher, senior scientific consultant, health economics, Oxford Outcomes, will address the meeting as president of ISPOR.

ICON acquired Oxford Outcomes in January 2011 to expand its late phase and outcomes research capabilities. In January 2012, ICON strengthened its expertise in value based pricing and market access through the acquisition of PriceSpective. Together with Oxford Outcomes and PriceSpective, ICON now offers a broad suite of integrated services to support early-stage, pre-launch and post-launch decision making.